Turn Therapeutics Inc.
TTRX
$6.93
$0.111.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.88% | -- | |||
| Gross Profit | 3.88% | -- | |||
| SG&A Expenses | -47.34% | 23.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -35.93% | 40.60% | |||
| Operating Income | 35.93% | -40.60% | |||
| Income Before Tax | -447.90% | 114.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -447.90% | 114.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -447.90% | 114.66% | |||
| EBIT | 35.93% | -40.60% | |||
| EBITDA | 36.13% | -40.87% | |||
| EPS Basic | -435.71% | 114.39% | |||
| Normalized Basic EPS | -437.70% | 114.35% | |||
| EPS Diluted | -435.71% | 114.39% | |||
| Normalized Diluted EPS | -437.70% | 114.35% | |||
| Average Basic Shares Outstanding | 3.69% | 1.61% | |||
| Average Diluted Shares Outstanding | 3.69% | 1.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||